Result of AGM

RNS Number : 0704A

ValiRx PLC

27 May 2021

 

27 May 2021

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Result of AGM

London, UK - ValiRx plc (AIM:VAL), a clinical stage drug development company announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

Ends

For further information please contact:

ValiRx plc	Tel: [phone] www.valirx.com
Suzanne Dilly, CEO	[e-mail]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: [phone]
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker	Tel: [phone]
Optimum Strategic Communications Supriya Mathur/ Shabnam Bashir	Tel: [phone] [e-mail]

About ValiRx plc

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.    https://www.valirx.com/

 

END

 

 

RAGSEIFFWEFSELI